Panel Discussion: Challenging the Definition of Unmet Need in Modern CKD to Reveal Where the Next Generation of Therapies Can Still Transform Outcomes
8:00 am - Wednesday 17th March 2027
- Debating whether current standards of care are approaching diminishing returns for broad CKD populations
- Identifying residual biological and clinical risk that remains despite SGLT2, MRA, incretin and other therapies
- Prioritizing where new mechanisms can deliver clinically meaningful rather than incremental benefit and going beyond laboratory measures for quality-of-life considerations
Speakers:
Senior Vice President - Clinical Development, Medical Lead - Complement Therapeutics
Nuvectis Pharma
